Humacyte, Inc

Recognized for innovation or featured in:

Humacyte Vascular Graft

Investigating The Potential For Longer Patency

Pre-clinical data suggests Humacyte investigational biologic grafts may have the potential to extend patency with:

  • The Possibility Of Some Reduction In Inflammation
  • The Possibility Of Some Reduction In Clotting and Thrombosis
Humacyte bioengineered blood vessel graft

Investigating The Potential For Being Less Immunogenic

Pre-clinical data suggests Humacyte investigational biologic grafts may have the potential to be less immunogenic with:

  • The Possibility Of Some Reduction In Foreign Body Response
  • The Possibility Of Some Reduction In The Need for Rx Transplant Therapy
Vein graft implant

Investigating The Potential For Lowering Healthcare Costs

Pre-clinical data suggests the possibility that Humacyte investigational biologic may have the potential of lowering healthcare costs with:

  • The Possibility Of Some Reduction In Surgical Interventions
  • The Possibility Of Long Term Clinical Outcomes

Developed From Core Technology

Humacyte, a privately held company, is primarily focused on developing investigational products for vascular disease and for replacement of anatomical conduits.  The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based investigational tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. Incorporated in late 2004, Humacyte licensed technology from MIT and Duke University. Since then, Humacyte has made considerable progress in the development and pre-clinical testing of our investigational biologic vascular grafts.

 Read More